Difference between revisions of "Cancer antigen 125"
Jump to navigation
Jump to search
(create) |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Positive== | ==Positive== | ||
*[[Serous carcinoma]]. | *[[Ovarian carcinoma]] ~ 75% of cases.<ref name=pmid16224215/> | ||
**[[Serous carcinoma of the ovary]] ~ 95% of cases.<ref name=pmid16224215/> | |||
*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal | last1 = Jiang | first1 = K. | last2 = Tan | first2 = E. | last3 = Sayegh | first3 = Z. | last4 = Centeno | first4 = B. | last5 = Malafa | first5 = M. | last6 = Coppola | first6 = D. | title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. | journal = Appl Immunohistochem Mol Morphol | volume = | issue = | pages = | month = Apr | year = 2016 | doi = 10.1097/PAI.0000000000000368 | PMID = 27093451 }}</ref> | |||
*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal | last1 = Lee | first1 = HI. | last2 = Kang | first2 = KH. | last3 = Cho | first3 = YM. | last4 = Lee | first4 = OJ. | last5 = Ro | first5 = JY. | title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. | journal = Arch Pathol Lab Med | volume = 130 | issue = 6 | pages = 871-4 | month = Jun | year = 2006 | doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 | PMID = 16740043 }}</ref> | |||
==Positive/negative== | |||
*[[Cholangiocarcinoma]] - 30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal | last1 = Higashi | first1 = M. | last2 = Yamada | first2 = N. | last3 = Yokoyama | first3 = S. | last4 = Kitamoto | first4 = S. | last5 = Tabata | first5 = K. | last6 = Koriyama | first6 = C. | last7 = Batra | first7 = SK. | last8 = Yonezawa | first8 = S. | title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. | journal = Pathobiology | volume = 79 | issue = 2 | pages = 101-6 | month = | year = 2012 | doi = 10.1159/000335164 | PMID = 22286058 }}</ref>. | |||
==Usually negative== | |||
*[[Breast carcinoma]] ~15% of cases show weak focal positivity.<ref name=pmid16224215>{{Cite journal | last1 = Tornos | first1 = C. | last2 = Soslow | first2 = R. | last3 = Chen | first3 = S. | last4 = Akram | first4 = M. | last5 = Hummer | first5 = AJ. | last6 = Abu-Rustum | first6 = N. | last7 = Norton | first7 = L. | last8 = Tan | first8 = LK. | title = Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. | journal = Am J Surg Pathol | volume = 29 | issue = 11 | pages = 1482-9 | month = Nov | year = 2005 | doi = | PMID = 16224215 }}</ref> | |||
==See also== | ==See also== | ||
Latest revision as of 21:32, 5 August 2016
Cancer antigen 125, abbreviated CA125 and CA-125, is a common immunostain and serum marker of disease. It is also known as mucin 16 and officially abbreviated MUC16.[1][2]
It is elevated in the serum in ovarian cancer and mildly or moderately elevated in endometriosis.
Positive
- Ovarian carcinoma ~ 75% of cases.[3]
- Serous carcinoma of the ovary ~ 95% of cases.[3]
- Pancreatic ductal adenocarcinoma.[4]
- Epithelioid sarcoma - reported.[5]
Positive/negative
- Cholangiocarcinoma - 30 +ve of 63 cases[6].
Usually negative
- Breast carcinoma ~15% of cases show weak focal positivity.[3]
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 606154
- ↑ URL: http://www.ncbi.nlm.nih.gov/gene/94025. Accessed on: 3 August 2016.
- ↑ 3.0 3.1 3.2 Tornos, C.; Soslow, R.; Chen, S.; Akram, M.; Hummer, AJ.; Abu-Rustum, N.; Norton, L.; Tan, LK. (Nov 2005). "Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.". Am J Surg Pathol 29 (11): 1482-9. PMID 16224215.
- ↑ Jiang, K.; Tan, E.; Sayegh, Z.; Centeno, B.; Malafa, M.; Coppola, D. (Apr 2016). "Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.". Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000368. PMID 27093451.
- ↑ Lee, HI.; Kang, KH.; Cho, YM.; Lee, OJ.; Ro, JY. (Jun 2006). "Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity.". Arch Pathol Lab Med 130 (6): 871-4. doi:10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2. PMID 16740043.
- ↑ Higashi, M.; Yamada, N.; Yokoyama, S.; Kitamoto, S.; Tabata, K.; Koriyama, C.; Batra, SK.; Yonezawa, S. (2012). "Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type.". Pathobiology 79 (2): 101-6. doi:10.1159/000335164. PMID 22286058.